Renal Denervation for Management of High Blood Pressure – Latest News

• 24-Jan-14

Medtronic’s sham-controlled renal denervation study, SYMPLICITY HTN-3, has failed to meet its primary efficacy endpoint of significantly reducing office blood pressure between baseline and six months in patients with treatment-resistant hypertension and systolic blood pressure of ≥160mmHg. (Source Vascularnews, Friday 10th, 2014) Covidien announced this past week that it is exiting the Renal Denervation program and is going to halt its RAPID II program. What this......

Read More